Blindspot by GroundNews BioNTech to Buy CureVac for $1.25 Billion to Boost Cancer Arm Published 3 months ago on June 13, 2025 By The Janitor BioNTech SE agreed to buy former Covid vaccine rival CureVac NV for about $1.25 billion in an all-stock transaction that will boost its growing oncology business. Related Topics: Up Next EU Rights Court Says Italy Not Responsible for Libyan Coast Guard Actions over Migrant Boat Sinking Don't Miss UN agencies say a violence-hit part of South Sudan is on the brink of famine The Janitor Continue Reading You may like
